Results 141 to 150 of about 156,077 (286)

“Buprenorphine doesn't hold me”: Neurochemical afterlives of state violence and the struggle for meaning in addiction treatment

Medical Anthropology Quarterly, EarlyView.
Abstract This paper analyzes two disparate experiences of buprenorphine, a medication for opioid addiction, in California. Within the context of the U.S. War on Drugs and after decades of criminalization, buprenorphine represents a shift toward outpatient medical treatment of opioid addiction, but it has been unequally distributed and experienced ...
Lauren Textor
wiley   +1 more source

Exploring metacognitive function in patients with opioid use disorder: A pilot study

Psychology and Psychotherapy: Theory, Research and Practice, EarlyView.
Abstract Objectives Despite recognised cognitive deficits related to substance use, as well as high mortality and treatment attrition rates, metacognition has never been studied in patients with opioid use disorder (OUD) undergoing opioid maintenance treatment (OMT).
John Hanson Högberg, Björn Philips, Jonas Stålheim, Kristina Berglund   +3 more
wiley   +1 more source

Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms

Psychiatry and Clinical Neurosciences, EarlyView.
Addiction is a chronic relapsing condition characterized by compulsive reward seeking and impaired behavioral control, associated with major individual and societal burden. Mechanistic investigation in humans remains constrained by ethical limitations, uncontrolled exposure histories, and ecological confounds.
Vanessa Fleury, Elvira Pirondini, Damien Benis, Tiffany Corbet, Gabriel Thorens, Christian Lüscher, Paul Krack   +6 more
wiley   +1 more source

Leveraging an Unhappiness Lens for Smarter Policies

Policy Studies Journal, EarlyView.
ABSTRACT Traditional policy research has largely focused on enhancing happiness or well‐being, privileging positive outcomes as the primary metric of success. We argue that a systematic focus on the drivers of unhappiness—rather than solely on happiness—offers a complementary analytical framework that can uncover hidden societal deficits and broaden ...
Marine Coupaud, Gilles Grolleau, Naoufel Mzoughi   +2 more
wiley   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1092-1100, October 2026.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley   +1 more source

Opioid Overdose Epidemic Modeling [PDF]

The opioid overdose crisis in the United States has led to thousands of lost lives and thousands more people struggling with opioid dependence. Disease modeling allows researchers to examine the course that the disease may take and to investigate ...
Spence, Chelsea
core   +1 more source

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

Addiction, Volume 121, Issue 10, Page 2607-2619, October 2026.
Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw, Suleyman Shah, India Olchefske, Louise M. Paterson, Mike J. Crawford, Anne Lingford‐Hughes   +5 more
wiley   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, Volume 121, Issue 10, Page 2794-2806, October 2026.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, Volume 121, Issue 10, Page 2620-2632, October 2026.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source